September 22, 2016 – The pharmacologically active compound known as sildenafil is largely used to treat erectile dysfunction (on the market for this indication under the trade name Viagra) and pulmonary arterial hypertension (on the market for this indication under the trade name Revatio) in …

Granpidam: A generic to Sildenafil (Revatio) Read more »

Tagged with: , , , , , , , , , ,

February 14, 2016 – Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have …

SGLT2 inhibitors and diabetic ketoacidosis: PRAC makes recommendations to minimise risk to patients Read more »

Tagged with: , , , , , , , , , , , , , ,

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in …

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation Read more »

Tagged with: , , , , , , ,

December 24, 2015 – The American Food and Drug Administration (FDA) just approved Lesinurad  (Zurampic) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a …

Is there help for patients suffering from gout? Lesinurad (Zurampic) approved for the treatment of high blood uric acid levels Read more »

Tagged with: , , , , , , , , ,

October 10, 2014 – The European Medicines Agency recently has recommended the authorisation of Harvoni (ledipasvir / sofosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection in adults. HCV infection is a major European public-health challenge. It affects between …

CHMP recommended Harvoni [Ledipasvir / Sofosbuvir] for the treatment of chronic hepatitis C Read more »

Tagged with: , , ,

July 10, 2014 – The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed daclatasvir (Daklinza, Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection, in combination with other drugs. Daclatasvir is …

EMA: EU Panel Endorses Daclatasvir (Daklinza) for Chronic Hepatitis C Infection Read more »

Tagged with: , , ,